The Sandiganbayan has allowed the case against Pharmally Pharmaceuticals to be refilled, following the withdrawal by the Office of the Ombudsman of its original complaint, with the principle of double jeopardy not being applicable to the case, according to the anti-graft court. The Sandiganbayan rejected claims by Pharmally Pharmaceuticals of political persecution and lack of due process while giving credence to the petition of the Ombudsman to withdraw the graft cases against …
Read More »
The Market Monitor Minding the Nation's Business